Pancreatic Cancer Research

ResearcherHenry Ford HealthActive in the last 2 years

Jie Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7870-0646; OpenAlex author ID A5100440013. Sources: OpenAlex.

Their work

Papers
7 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 7

  1. Oncolytic virus-induced IL-1β+ monocyte-IL-6+ CAF axis suppresses dendritic cell-mediated antitumor immunity in pancreatic cancer. Co-author DOI 10.1136/jitc-2025-013175↗
  2. Corrigendum to "scRNA-Seq and imaging mass cytometry analyses unveil iNKT cells-mediated anti-tumor immunity in pancreatic cancer liver metastasis" [Cancer Let… First author DOI 10.1016/j.canlet.2024.217071↗
  3. Long noncoding RNA LINC00857 promotes pancreatic cancer proliferation and metastasis by regulating the miR-130b/RHOA axis. Co-author DOI 10.1038/s41420-022-01008-2↗
  4. [6]-Paradol suppresses proliferation and metastases of pancreatic cancer by decreasing EGFR and inactivating PI3K/AKT signaling. First author DOI 10.1186/s12935-021-02118-0↗
  5. Hypoxia-Induced ZWINT Mediates Pancreatic Cancer Proliferation by Interacting With p53/p21. Co-author DOI 10.3389/fcell.2021.682131↗
  6. Long noncoding RNA LINC01559 promotes pancreatic cancer progression by acting as a competing endogenous RNA of miR-1343-3p to upregulate RAF1 expression. First author DOI 10.18632/aging.103487↗
  7. miR-1181 inhibits invasion and proliferation via STAT3 in pancreatic cancer. Co-author DOI 10.3748/wjg.v23.i9.1594↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jianxin Jiang · 3 shared papers, 2017–2021 · strength 0.38
  2. Zhiwei He · 2 shared papers, 2021 · strength 0.28
  3. Xueyi Jiang · 2 shared papers, 2021 · strength 0.28
  4. Jian Xu · 2 shared papers, 2021 · strength 0.28
  5. Yankun Chen · 2 shared papers, 2021 · strength 0.28
  6. Xinyuan Liu · 2 shared papers, 2021 · strength 0.28
  7. Peng Chen · 2 shared papers, 2021 · strength 0.28
  8. Bin Chen · 1 shared paper, 2024 · strength 0.19
  9. Qing‐Sheng Mi · 1 shared paper, 2024 · strength 0.19
  10. Ian M. Loveless · 1 shared paper, 2024 · strength 0.19
  11. Qijun Yi · 1 shared paper, 2024 · strength 0.19
  12. Howard C. Crawford · 1 shared paper, 2024 · strength 0.19
  13. Fan Li · 1 shared paper, 2025 · strength 0.19
  14. Shiyu Liu · 1 shared paper, 2025 · strength 0.19
  15. Yuanke Li · 1 shared paper, 2025 · strength 0.19
  16. Youjia Cao · 1 shared paper, 2025 · strength 0.19
  17. Hongkai Zhang · 1 shared paper, 2025 · strength 0.19
  18. Feilong Zhou · 1 shared paper, 2025 · strength 0.19
  19. Zhaoyuan Zhang · 1 shared paper, 2025 · strength 0.19
  20. Zhangxia Ren · 1 shared paper, 2022 · strength 0.16
  21. Zhirui Zeng · 1 shared paper, 2022 · strength 0.16
  22. Peng Chen · 1 shared paper, 2022 · strength 0.16
  23. Wenpeng Cao · 1 shared paper, 2022 · strength 0.16
  24. Shan Lei · 1 shared paper, 2022 · strength 0.16
  25. Qin Yang · 1 shared paper, 2020 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.